THE FIRST CLINICAL EXPERIENCE WITH AFATINIB IN RUSSIAN FEDERATION

THE FIRST CLINICAL EXPERIENCE WITH AFATINIB IN RUSSIAN FEDERATION

Randomized clinical trials results have shown the advantage of non-selective EGFR tyrosine kinase inhibitor 2nd generation – afatinib compared with platinum-based chemotherapy in adenocarcinoma EGFR-positive patients in both the first and second-line of treatment. Shown significant improvement in PF...

Full description

Bibliographic Details
Main Authors: К. К. LAKTIONOV, М. V. PEREGUDOVA, V. V. BREDER, E. V. REUTOVA, D. A. PEREGUDOV, M. S. ARDZINBA, P. A. CHERNENKO, D. T. MARINOV
Format: Article
Language:Russian
Published: Remedium Group LLC 2016-12-01
Series:Медицинский совет
Subjects:
non-small-cell lung cancer
adenocarcinoma
egfr mutation
del19
l858r
afatinib
Online Access:https://www.med-sovet.pro/jour/article/view/1407

Internet

https://www.med-sovet.pro/jour/article/view/1407

Similar Items